IRW-News: FAST DOSE THERAPY: Rapid Dose Therapeutics and Thrive Cannabis Sign Manufacturing Agreement for QuickStrip Cannabis Products

IRW-PRESS: FAST DOSE THERAPY: Rapid Dose Therapeutics and Thrive Cannabis Sign Manufacturing Agreement for QuickStrip Cannabis Products

Burlington, Ontario, Brantfort, Ontario – August 08, 2019 – Rapid Dose Therapeutics Corp. (RTD) announced today the signing of a manufacturing agreement with Thrive Cannabis for the manufacture of QuickStrip cannabis products for the Canadian medical and leisure market. This agreement is therefore another element of the growth strategy adopted by RTD.

The QuickStrip RTD methodology is a dissolving, sublingual, fast-dissolving pharmaceutical grade drug delivery system designed for medical and recreational consumers with the slogan Anytime-Anywhere.

"This agreement demonstrates our commitment to providing Canadian medical and recreational cannabis consumers with a non-smoking alternative with a patented, fast, convenient, accurate and discreet patented administration method," said Mark Upsdell, CEO of RTD. "RTD will further expand our strategic partnerships and unique position in the cannabis industry, and this agreement with Thrive also demonstrates that QuickStrip is a desirable delivery option for Canadian consumers, while offering health benefits and benefits concrete, "said Upsdell. added.

Thrive expects to devote a significant portion of its high quality distillate to the production of QuickStrip by first launching it under its brand name GreyBeard, then adding a QuickStrip product aimed at women. Thrive will also be responsible for producing new medical and consumer brands for other licensed Canadian producers.

Todd Masse, CCO of Thrive, says, "This agreement allows Thrive to ensure full coverage of demand where there are gaps." All Canadians should have access to the QuickStrip Administration Method. "The agreement with RDT will allow Thrive to offer QuickStrip administration." QuickStrip, which offers products to a wide range of cannabis users in Canada, allows us to offer consumers and patients a smoke-free, odor-free, and stigmatized alternative. "In addition," in the coming weeks, we will explore the possibilities of white label agreements with other major cannabis producing companies. "

About rapid dose therapy

Rapid Dose Therapeutics, RTD, is a Canadian life sciences company that offers innovative and proprietary drug delivery technology. The goal is to improve outcomes for patients and quality of life. The main product of Rapid Dose Therapeutics is QuickStrip, a rapid release oral drug delivery system. RTD is specialized and engaged in clinical research and product development for the health sector – for the administration of nutraceuticals, pharmaceuticals and cannabis. In the cannabis sector, RDT offers a turnkey managed treatment program that enables QuickStrip RTD drug delivery technology to be licensed by selected clients. License agreements based on RTD volume generate high recurring revenues. This will allow for rapid expansion in emerging markets, which will bring added value to consumers and investors. Rapid Dose Therapeutics strives to continuously develop innovative solutions that meet the different segments and needs of the market.

More information on www.rapiddose.ca

Media contact for investors:

Mark Upsdell, CEO


Fast dose therapeutic


mupsdell@rapid-dose.com


Tel: +1 (416) 477-1052


Ali Mahdavi, Executive Director

Spinnaker Capital Markets Inc.

am@spinnakercmi.com-

Tel: +1 (416) 962-3300

Social media

RapidDoseTherapeutics.linkedin

RapidDoseTherapeutics.twitter

RapidDoseTherapeutics.facebook

QuickStrip.instagram

About Cannabis Thrive

Thrive Cannabis is currently developing high-end brands for the Canadian leisure market, which will be available for distribution beginning in 2020. TerraFarma is a vertically integrated private farmer that produces high quality cannabis in the high-end market. Founded in 2018, the company now has manufacturing facilities in Jarvis, Ontario. Thrive Cannabis, a wholly-owned subsidiary of TerraFarma, owns the production, sales and outdoor licenses of Health Canada.

For more information on TerraFarma or Thrive Cannabis, please visit www.thrivecannabis.ca

FUTURE PROSPECTS FOR FUTURE DECLARATIONS: Certain information in this press release may contain forward-looking information within the meaning of applicable securities laws. All statements in this press release that are not statements of historical fact may be considered forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potentially", "believe", "intend to", or the negative of these terms and similar terms. Statements containing forward-looking information, including the provision of products using the QuickStrip product delivery methodology, at the time of publication of this press release, represent and should reflect the plans, estimates, forecasts, forecasts, expectations or beliefs of the RTD on future events or results deemed appropriate based on the information currently available to them. Forward-looking statements inevitably involve known and unknown risks, including risks related to general economic conditions, adverse industry events, marketing costs, market losses, future legislative and regulatory developments related to cannabis. unable to obtain sufficient capital from internal and external sources. to maintain and / or the inability to obtain sufficient capital on favorable terms, the Canadian cannabis industry in general, income tax and regulatory issues, the ability to implement its business strategies, competition, exchange rate and interest rate fluctuations and other risks. Readers are cautioned that the above list is not exhaustive. There can be no assurance that forward-looking statements that management believes are reasonable at the time of preparation can not be considered accurate because there can be no assurance that the plans, intentions or expectations on which they are based. will enter. Actual results and future events may differ materially from those anticipated in these statements. Readers should not rely too much on forward-looking information. The forward-looking statements contained in this press release are expressly limited by these disclaimers.

The original message in English can be found on the following link:

https://www.irw-press.at/press_html.aspx?messageID=48532

The translated message can be found on the following link:

https://www.irw-press.at/press_html.aspx?messageID=48532&tr=1

NEWSLETTER SIGN-UP:

Current press releases from this company directly in your mailbox:

http://www.irw-press.com/alert_subscription.php?lang=de&isin=CA75339A1012

Message submitted by IRW-Press.com. The sender is responsible for the content.

Free reprint with indication of authorized sources.